DIABETIC MACULAR EDEMA

This study tests a small, refillable implant placed in the eye that delivers medication every 24 weeks, compared to standard monthly eye injections. It includes about 634 adults with diabetic macular edema, a condition that causes vision loss. The goal is to see if the implant wo…

This early-stage study tests a new drug, RO7497372, given as an eye injection for people with diabetic macular edema (DME), a condition that causes vision loss. The trial involves 151 participants and aims to check the drug's safety, how long it stays in the eye and blood, and it…

This study tests a drug called faricimab (VABYSMO) in 218 people with diabetic macular edema who have not been treated before. The participants are Black/African American, Hispanic/Latino American, Native American/Alaska Native/Native Hawaiian/Pacific Islander, or Asian Indian. T…

This study tests a new eye injection called IBI302 for people with diabetic macular edema, a condition that causes vision loss due to diabetes. About 150 adults aged 18-80 with type 1 or 2 diabetes and swelling in the center of the retina will receive either IBI302 or an active c…

This study tests whether a pre-filled syringe is as safe as the traditional vial when giving the medicine bevacizumab for certain eye diseases. About 120 people with wet age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion will receive inject…

This study compares two ways of giving faricimab, a drug injected into the eye, to treat diabetic macular edema (DME). One group gets injections on a fixed monthly schedule, while the other uses a 'treat and extend' approach where the time between injections is gradually lengthen…

This Phase 2 trial tests whether the oral drug tonabersat can reduce retinal swelling in people with diabetic macular edema who still have good vision. About 128 adults with type 1 or 2 diabetes will take either tonabersat or a placebo daily for several months. The main goal is t…

This phase 2 study tests a new treatment plan for diabetic macular edema, a condition that causes vision loss. Instead of waiting for severe swelling, patients receive two dexamethasone implants 12 weeks apart, then additional injections only as needed. The goal is to improve vis…

This study tests a higher dose of the drug aflibercept (8 mg) given as an eye injection every 4 weeks to people with wet age-related macular degeneration (nAMD) or diabetic macular edema (DME). The goal is to see if this dosing schedule is safe and works well for those who have a…

This phase 2 trial tests a gene therapy called 4D-150 for diabetic macular edema, a condition that causes vision loss in people with diabetes. The study involves 72 adults who will receive either the gene therapy or standard aflibercept injections. The goal is to see if a single …

This study is collecting long-term, real-world data from about 6,000 adults being treated with Roche eye medications (Faricimab or the Port Delivery System with Ranibizumab) for conditions like wet age-related macular degeneration and diabetic macular edema. The goal is to unders…

This study follows 1,000 patients in China who are already receiving faricimab for diabetic macular edema, retinal vein occlusion, or wet age-related macular degeneration. Researchers will collect data from routine clinic visits over one year to see how well the drug works and ho…

This observational study follows about 236 adults with diabetic macular edema (DME) who did not respond well to anti-VEGF injections and are now starting treatment with a dexamethasone implant (DEX-I). The implant slowly releases steroid medication into the eye. Researchers will …

This study follows 110 adults with diabetic macular edema who are prescribed OZURDEX (a dexamethasone implant placed in the eye) by their doctors in routine Chinese clinics. Researchers will track side effects like cataracts, high eye pressure, and bleeding over two years. The go…